ALK and neuroblastoma: Improvements in HR-NB patient survival have been achieved with intensification of HDC and immunotherapy with dinutuximab (ch14.18/Sp02 and ch14.18/CH0),3-5,7 and our results highlight the potential of ALK inhibition as an attractive upfront precision-medicine strategy in patients with ALK alterations to further improve survival.